Paradigm Shifts in Alpha-1-Antitrypsin Deficiency (AATD) and Impact on Patient Management

This activity is older than 12 months.

These educational modules have been developed with the assistance of Prof. Daiana Stolz (Department of Pneumology, Medical Center – University of Freiburg, Germany) and Prof. Felix Herth (Department of Pneumology and Internal Medicine, Thoracic Clinic, University of Heidelberg, Germany). This program was supported by CSL Behring.

For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Please note that products may have different labeling according to geographical location. Within Europe, full prescribing information is available from the European Medicines Agency (ema.europa.eu) and in the USA, from the US Food and Drug Administration (fda.gov).

All characters and events depicted in this patient case simulation are entirely fictitious. Any similarity to actual events or persons, living or dead, is purely coincidental. This activity is intended for a global audience of healthcare professionals. To proceed, please confirm that you are a healthcare professional.

Modules

• A 53-year-old man with early diagnosis and management of AATD in an adult patient

• A 50-year-old woman with treatment considerations in a young patient with AATD and emphysema

• A 68-year-old woman with unmet needs in AATD in an elderly patient in a pulmonology setting

• A 10 -year-old boy with AATD in pediatric patients: Disease awareness for early diagnosis